BR112022010574A2 - Composições farmacêuticas compreendendo cabotegravir - Google Patents
Composições farmacêuticas compreendendo cabotegravirInfo
- Publication number
- BR112022010574A2 BR112022010574A2 BR112022010574A BR112022010574A BR112022010574A2 BR 112022010574 A2 BR112022010574 A2 BR 112022010574A2 BR 112022010574 A BR112022010574 A BR 112022010574A BR 112022010574 A BR112022010574 A BR 112022010574A BR 112022010574 A2 BR112022010574 A2 BR 112022010574A2
- Authority
- BR
- Brazil
- Prior art keywords
- cabotegravir
- pharmaceutical compositions
- compositions including
- relates
- treatment
- Prior art date
Links
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 title abstract 3
- 229950005928 cabotegravir Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945412P | 2019-12-09 | 2019-12-09 | |
| US202062982305P | 2020-02-27 | 2020-02-27 | |
| PCT/IB2020/061582 WO2021116872A1 (en) | 2019-12-09 | 2020-12-07 | Pharmaceutical compositions comprising cabotegravir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010574A2 true BR112022010574A2 (pt) | 2022-08-23 |
Family
ID=73834567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010574A BR112022010574A2 (pt) | 2019-12-09 | 2020-12-07 | Composições farmacêuticas compreendendo cabotegravir |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230045509A1 (https=) |
| EP (1) | EP4072520B1 (https=) |
| JP (1) | JP7703538B2 (https=) |
| KR (1) | KR20220112771A (https=) |
| CN (1) | CN114786648A (https=) |
| AU (1) | AU2020402659A1 (https=) |
| BR (1) | BR112022010574A2 (https=) |
| CA (1) | CA3164528A1 (https=) |
| ES (1) | ES3051362T3 (https=) |
| IL (1) | IL293566A (https=) |
| MX (1) | MX2022006940A (https=) |
| TW (1) | TW202135815A (https=) |
| UY (1) | UY38982A (https=) |
| WO (1) | WO2021116872A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2025068743A1 (en) * | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| US11718637B2 (en) * | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| CN115397424A (zh) * | 2020-04-15 | 2022-11-25 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| WO2022051198A1 (en) | 2020-09-01 | 2022-03-10 | Viiv Healthcare Company | Combination of cabotegravir and levonorgestrel |
| US20250296988A1 (en) * | 2020-12-07 | 2025-09-25 | Viiv Healthcare Company | Combination therapy |
| CA3241017A1 (en) * | 2021-12-17 | 2023-06-22 | Robert Ferris | Combination therapies for hiv infections and uses thereof |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121909019A (zh) | 2023-09-27 | 2026-04-21 | Viiv保健英国第三有限公司 | 药物组合物 |
| WO2025128498A1 (en) * | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Pharmaceutical compositions |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202602442A (zh) | 2024-03-01 | 2026-01-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 | 給藥方案 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| US8129385B2 (en) | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| US20170165271A1 (en) * | 2014-02-24 | 2017-06-15 | The Board Of Regents Of The University Of Nebraska | Compositions and Methods for the Delivery of Therapeutics |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| SI3129392T1 (sl) * | 2014-04-11 | 2020-11-30 | VIIV Healthcare UK(No.4) Limited | Triterpenoidi z inhibitorno aktivnostjo maturacije HIV-a, substituirani na položaju 3 z nearomatskim obročem, ki nosi haloalkilni substituent |
| US10092523B2 (en) * | 2014-09-26 | 2018-10-09 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| CN109195633A (zh) * | 2016-02-12 | 2019-01-11 | 西普拉有限公司 | 包含抗逆转录病毒药物和药代动力学增效剂的药物组合物 |
| EP4299133A3 (en) * | 2016-06-23 | 2024-03-13 | VIIV Healthcare Company | Compositions and methods for the delivery of therapeutics |
| WO2018002902A1 (en) * | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| ES2970042T3 (es) * | 2018-04-24 | 2024-05-24 | Viiv Healthcare Uk No 5 Ltd | Compuestos con actividad inhibidora de la maduración del VIH |
| CN120053445A (zh) * | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| WO2020112931A1 (en) * | 2018-11-29 | 2020-06-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| AU2020231934B2 (en) * | 2019-03-06 | 2023-04-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in HIV therapy |
| EP3962603A1 (en) * | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| LT3986561T (lt) * | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
| PE20221037A1 (es) * | 2019-09-11 | 2022-06-17 | Scripps Research Inst | Profarmacos antivirales y composiciones farmaceuticas de los mismos |
-
2020
- 2020-12-07 UY UY0001038982A patent/UY38982A/es not_active Application Discontinuation
- 2020-12-07 TW TW109143111A patent/TW202135815A/zh unknown
- 2020-12-07 IL IL293566A patent/IL293566A/en unknown
- 2020-12-07 WO PCT/IB2020/061582 patent/WO2021116872A1/en not_active Ceased
- 2020-12-07 AU AU2020402659A patent/AU2020402659A1/en not_active Abandoned
- 2020-12-07 CN CN202080085115.9A patent/CN114786648A/zh active Pending
- 2020-12-07 CA CA3164528A patent/CA3164528A1/en active Pending
- 2020-12-07 BR BR112022010574A patent/BR112022010574A2/pt not_active Application Discontinuation
- 2020-12-07 KR KR1020227018750A patent/KR20220112771A/ko not_active Withdrawn
- 2020-12-07 MX MX2022006940A patent/MX2022006940A/es unknown
- 2020-12-07 JP JP2022534860A patent/JP7703538B2/ja active Active
- 2020-12-07 US US17/756,971 patent/US20230045509A1/en active Pending
- 2020-12-07 EP EP20824345.1A patent/EP4072520B1/en active Active
- 2020-12-07 ES ES20824345T patent/ES3051362T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114786648A (zh) | 2022-07-22 |
| ES3051362T3 (en) | 2025-12-26 |
| EP4072520B1 (en) | 2025-09-24 |
| KR20220112771A (ko) | 2022-08-11 |
| MX2022006940A (es) | 2022-07-11 |
| US20230045509A1 (en) | 2023-02-09 |
| CA3164528A1 (en) | 2021-06-17 |
| WO2021116872A1 (en) | 2021-06-17 |
| JP7703538B2 (ja) | 2025-07-07 |
| IL293566A (en) | 2022-08-01 |
| TW202135815A (zh) | 2021-10-01 |
| AU2020402659A1 (en) | 2022-06-02 |
| EP4072520A1 (en) | 2022-10-19 |
| UY38982A (es) | 2021-06-30 |
| JP2023505543A (ja) | 2023-02-09 |
| EP4072520C0 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010574A2 (pt) | Composições farmacêuticas compreendendo cabotegravir | |
| BR112015013695A2 (pt) | composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv | |
| DOP2021000195A (es) | Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico | |
| JOP20170135A1 (ar) | مركبات ديازاسبيروألكيل مثيل-إندول | |
| TR201909152T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı. | |
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| PH12016500389B1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
| MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| BR112017017500A2 (pt) | derivado de quinolina para uso no tratamento e prevenção de infecções virais | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| BR112017006005A2 (pt) | composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv. | |
| BR112022010826A2 (pt) | Anticorpos amplamente neutralizantes contra o hiv | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112021018707A2 (pt) | Formulações compreendendo melflufeno | |
| BR112022000417A2 (pt) | Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv | |
| MX388699B (es) | Formas cristalinas de cabotegravir de sodio | |
| AR122350A1 (es) | Composiciones farmacéuticas | |
| BR112017009853A2 (pt) | composto, composição, uso de uma quantidade melhoradora de hiv de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |